Valuation : Pelthos Therapeutics Inc.

Market Cap 94.68M 81.58M 76.49M 69.83M 132M 9.05B 132M 908M 354M 4.57B 355M 348M 15.15B P/E 2026 *
-1.44x
P/E 2027 * -8.79x
Enterprise Value 94.68M 81.58M 76.49M 69.83M 132M 9.05B 132M 908M 354M 4.57B 355M 348M 15.15B EV / Sales 2026 *
1.49x
EV / Sales 2027 * 0.84x
Free-Float
50.69%
Yield 2026 *
-
Yield 2027 * -
1 day-1.08%
1 week-3.06%
Current month-13.71%
1 month-10.95%
3 months-4.15%
6 months-6.18%
Current year-20.23%
1 week 24
Extreme 24
28.17
1 month 24
Extreme 24
29.8
Current year 18.19
Extreme 18.19
30.99
1 year 18.19
Extreme 18.19
37.5
3 years 4.5
Extreme 4.5
60
5 years 4.5
Extreme 4.5
60
10 years 4.5
Extreme 4.5
60
Date Insider Type Main position Quantity % Market Cap.
7/2/26 Sell

Director

-558 0.0161%
7/2/26 Sell

Director

-786 0.0226%
7/2/26 Sell

Chairman

-797 0.0229%
Change 5-day change 1-year change 3-year change Capi.($)
-1.08%-3.06%+7.57% - 95.71M
-0.13%-6.44%+60.47%+112.05% 1,048B
+0.85%-0.81%+52.77%+63.15% 640B
-1.03%-3.58%+22.87%+73.29% 456B
-1.46%-4.50%+37.43%+38.41% 362B
-0.72%-2.89%+21.86%+36.79% 295B
-1.19%-2.21%+1.35%+12.29% 255B
-1.05%-1.57%+51.40%+68.55% 236B
+0.08%-1.78%-17.64%-54.29% 204B
-2.14%-0.30%+29.42%+89.10% 185B
Average -0.80%-2.49%+26.75%+48.82% 368.17B
Weighted average by Cap. -0.49%-3.02%+38.56%+65.41%

Financials

2026 *2027 *
Net sales 63.75M 54.93M 51.5M 47.02M 88.57M 6.09B 88.85M 611M 238M 3.08B 239M 234M 10.2B 112M 96.7M 90.66M 82.76M 156M 10.73B 156M 1.08B 420M 5.41B 421M 412M 17.95B
Net income -62.08M -53.5M -50.16M -45.79M -86.25M -5.93B -86.53M -595M -232M -3B -233M -228M -9.93B -24.96M -21.5M -20.16M -18.41M -34.67M -2.39B -34.78M -239M -93.33M -1.2B -93.7M -91.66M -3.99B
Net Debt - -
Logo Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
Employees
92
Date Price Change Volume
26-08-28 US$24.73 -1.08% 40,908
26-08-27 US$25.00 -6.65% 83,493
26-08-26 US$26.78 -1.54% 36,434
26-08-25 US$27.20 +2.18% 50,927
26-08-24 US$26.62 +4.35% 151,268
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
24.73USD
Average target price
53.14USD
Spread / Average Target
+114.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTHS Stock